535
Views
15
CrossRef citations to date
0
Altmetric
Review

Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity

, , , , , & show all
Pages 259-271 | Received 13 Aug 2020, Accepted 07 Dec 2020, Published online: 11 Jan 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Abdelmoujoud Faris, Ibrahim M. Ibrahim, Hanine Hadni & Menana Elhallaoui. (2023) High-throughput virtual screening of phenylpyrimidine derivatives as selective JAK3 antagonists using computational methods. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-26.
Read now
Arnaud Bruyère, Marc Le Vée, Elodie Jouan, Stephanie Molez, Anne T. Nies & Olivier Fardel. (2021) Differential in vitro interactions of the Janus kinase inhibitor ruxolitinib with human SLC drug transporters. Xenobiotica 51:4, pages 467-478.
Read now

Articles from other publishers (13)

Anniina Virtanen, Maaria Palmroth, Sanna Liukkonen, Antti Kurttila, Teemu Haikarainen, Pia Isomäki & Olli Silvennoinen. (2023) Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling . Arthritis & Rheumatology 75:11, pages 2054-2061.
Crossref
Isabelle Melki & Marie-Louise Frémond. (2023) JAK Inhibition in Juvenile Idiopathic Arthritis (JIA): Better Understanding of a Promising Therapy for Refractory Cases. Journal of Clinical Medicine 12:14, pages 4695.
Crossref
T. Y. J. Appeldoorn, T. H. Oude Munnink, L. M. Morsink, M. N. Lub-de Hooge & D. J. Touw. (2023) Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review. Clinical Pharmacokinetics 62:4, pages 559-571.
Crossref
Fangrui Xiu, Magdalena Rausch, Zhibo Gai, Shanshan Su, Shijun Wang & Michele Visentin. (2023) The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of Tyrosine Kinase Inhibitors. International Journal of Molecular Sciences 24:3, pages 2101.
Crossref
David Malnoë, Olivier Fardel & Pascal Le Corre. (2022) Involvement of Transporters in Intestinal Drug–Drug Interactions of Oral Targeted Anticancer Drugs Assessed by Changes in Drug Absorption Time. Pharmaceutics 14:11, pages 2493.
Crossref
Adina EichnerJohannes Wohlrab. (2022) Pharmakologie der Januskinase‐Inhibitoren – Teil 1: Pharmakokinetik. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 20:11, pages 1485-1500.
Crossref
Adina Eichner & Johannes Wohlrab. (2022) Pharmacology of inhibitors of Janus kinases – Part 1: Pharmacokinetics. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 20:11, pages 1485-1499.
Crossref
Yasamin Kalantari, Sara Sadeghi, Delaram Asadi & Azadeh Goodarzi. (2022) A literature review on Janus kinase (JAK) inhibitors for the treatment of immunobullous disorders. International Immunopharmacology 110, pages 108923.
Crossref
S. Djabarouti, P. Mora, M. Lahouati, M. Gigan, N. d’Houdain, B. Sourisseau, J. Chambord & F. Xuereb. (2022) Intérêt des dosages pharmacologiques d’immunosuppresseurs et immunomodulateurs dans la prise en charge des maladies autoimmunes. La Revue de Médecine Interne 43:7, pages 412-418.
Crossref
Jérôme Hadjadj, Marie-Louise Frémond & Bénédicte Neven. (2021) Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity. Frontiers in Immunology 12.
Crossref
Alain Lescoat, David Roofeh, Masataka Kuwana, Robert Lafyatis, Yannick Allanore & Dinesh Khanna. (2021) Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. Clinical Reviews in Allergy & Immunology 64:3, pages 239-261.
Crossref
Milo Gatti, Eleonora Turrini, Emanuel Raschi, Piero Sestili & Carmela Fimognari. (2021) Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues. Pharmaceuticals 14:8, pages 738.
Crossref
Igor A. Schepetkin, Mark B. Plotnikov, Andrei I. Khlebnikov, Tatiana M. Plotnikova & Mark T. Quinn. (2021) Oximes: Novel Therapeutics with Anticancer and Anti-Inflammatory Potential. Biomolecules 11:6, pages 777.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.